ES2840923T3 - Anticuerpo anti-Siglec-15 - Google Patents

Anticuerpo anti-Siglec-15 Download PDF

Info

Publication number
ES2840923T3
ES2840923T3 ES10761710T ES10761710T ES2840923T3 ES 2840923 T3 ES2840923 T3 ES 2840923T3 ES 10761710 T ES10761710 T ES 10761710T ES 10761710 T ES10761710 T ES 10761710T ES 2840923 T3 ES2840923 T3 ES 2840923T3
Authority
ES
Spain
Prior art keywords
amino acid
seq
sequence
antibody
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10761710T
Other languages
English (en)
Spanish (es)
Inventor
Yoshiharu Hiruma
Eisuke Tsuda
Maikiko Nakayama
Takeschi Takizawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Application granted granted Critical
Publication of ES2840923T3 publication Critical patent/ES2840923T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES10761710T 2009-04-09 2010-04-07 Anticuerpo anti-Siglec-15 Active ES2840923T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009094613 2009-04-09
PCT/JP2010/056294 WO2010117011A1 (fr) 2009-04-09 2010-04-07 ANTICORPS ANTI-Siglec-15

Publications (1)

Publication Number Publication Date
ES2840923T3 true ES2840923T3 (es) 2021-07-07

Family

ID=42936292

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10761710T Active ES2840923T3 (es) 2009-04-09 2010-04-07 Anticuerpo anti-Siglec-15

Country Status (19)

Country Link
US (3) US8575316B2 (fr)
EP (2) EP3699277A1 (fr)
JP (2) JP5653909B2 (fr)
KR (1) KR101690340B1 (fr)
CN (2) CN102272306B (fr)
AU (2) AU2010235453B2 (fr)
BR (1) BRPI1006134A2 (fr)
CA (1) CA2750836C (fr)
CO (1) CO6420359A2 (fr)
ES (1) ES2840923T3 (fr)
IL (2) IL213943A (fr)
MX (2) MX2011007342A (fr)
MY (1) MY152033A (fr)
NZ (2) NZ593550A (fr)
RU (2) RU2539790C2 (fr)
SG (2) SG10201401331TA (fr)
TW (1) TWI468177B (fr)
WO (1) WO2010117011A1 (fr)
ZA (1) ZA201104545B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
HUE025262T2 (en) 2007-10-11 2016-02-29 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-linked Siglec-15 protein
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
US9447192B2 (en) 2011-09-09 2016-09-20 Medimmune Limited Anti-Siglec-15 antibodies and uses thereof
ES2660472T3 (es) * 2012-03-30 2018-03-22 Daiichi Sankyo Company, Limited Anticuerpo anti-Siglec-15 modificado con CDR
CN104321430A (zh) * 2012-03-30 2015-01-28 第一三共株式会社 新颖的抗-siglec-15抗体
JP6268173B2 (ja) 2012-07-19 2018-01-24 第一三共株式会社 抗Ｓｉｇｌｅｃ−１５抗体
JP6494519B6 (ja) 2013-09-30 2019-07-31 第一三共株式会社 抗ｌｐｓ ｏ１１抗体
WO2015192214A1 (fr) * 2014-06-18 2015-12-23 Alethia Biotherapeutics Inc. Anticorps anti-siglec-15 destinés à être utilisés dans le traitement de l'ostéogénèse imparfaite
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
CN110913905A (zh) * 2017-06-30 2020-03-24 国立大学法人北海道大学 不产生生长障碍的小儿骨质疏松症治疗药
MX2020000966A (es) 2017-07-27 2020-09-28 Daiichi Sankyo Co Ltd Anticuerpo anti-cd147.
EP3805389A4 (fr) 2018-05-31 2022-03-23 Daiichi Sankyo Company, Limited Anticorps anti-tlr7 humain
CA3107732A1 (fr) 2018-07-27 2020-01-30 Daiichi Sankyo Company, Limited Proteine reconnaissant la fraction medicamenteuse d'un conjugue anticorps-medicament
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN113817057B (zh) * 2020-06-19 2024-02-20 盛禾(中国)生物制药有限公司 一种抗siglec15抗体及其应用
CN112159475B (zh) * 2020-10-10 2021-04-30 南京凯地生物科技有限公司 Siglec-15单克隆抗体及其应用
CN114525256A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用
WO2022228183A1 (fr) * 2021-04-30 2022-11-03 杭州邦顺制药有限公司 Anticorps anti-siglec 15, son procédé de préparation et son utilisation
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
CN117736324B (zh) * 2022-09-22 2024-06-28 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体的纯化方法
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ES2313867T3 (es) 1991-12-02 2009-03-16 Medical Research Council Produccion de anticuerpos anti-auto de repertorios de segmentos de anticuerpo expresados en la superficie de fagos.
WO1993019172A1 (fr) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Procedes de production d'elements de paires de liaison specifiques
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (fr) 1993-12-03 1996-09-18 Medical Research Council Proteines et peptides de liaison recombines
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
RU2238949C2 (ru) 1997-04-15 2004-10-27 Санкио Компани Лимитед Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты)
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
EA013224B1 (ru) 2000-10-06 2010-04-30 Киова Хакко Кирин Ко., Лтд. Клетки, продуцирующие композиции антител
CA2428140A1 (fr) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Proteines secretees
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1369479A4 (fr) 2001-02-15 2004-12-08 Mochida Pharm Co Ltd Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
TR201809008T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
EP1456655A2 (fr) 2001-11-13 2004-09-15 Incyte Genomics, Inc. Recepteurs et proteines associees aux membranes
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1494714A4 (fr) 2002-04-05 2008-03-05 Amgen Inc Anticorps humain neutralisant anti opgl utilises en tant qu'inhibiteurs de chemin d'opgl
KR101024443B1 (ko) 2003-01-07 2011-03-23 심포젠 에이/에스 재조합 폴리클로날 단백질의 제조 방법
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
DK1994155T4 (da) 2006-02-13 2022-07-25 Daiichi Sankyo Co Ltd Polynukleotid- og polypeptidsekvenser involveret i fremgangsmåden med knogleremodellering
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
HUE025262T2 (en) 2007-10-11 2016-02-29 Daiichi Sankyo Co Ltd Antibody targeting osteoclast-linked Siglec-15 protein
KR101690340B1 (ko) 2009-04-09 2016-12-27 다이이찌 산쿄 가부시키가이샤 항 Ｓｉｇｌｅｃ-15 항체

Also Published As

Publication number Publication date
TWI468177B (zh) 2015-01-11
IL252561A0 (en) 2017-07-31
NZ593550A (en) 2013-11-29
RU2539790C2 (ru) 2015-01-27
RU2014147188A3 (fr) 2018-06-27
CN106317224B (zh) 2020-05-12
EP3699277A1 (fr) 2020-08-26
EP2377932B1 (fr) 2020-11-18
AU2010235453A1 (en) 2011-07-28
AU2010235453B2 (en) 2013-10-03
CN102272306A (zh) 2011-12-07
RU2011128332A (ru) 2013-01-20
CA2750836C (fr) 2018-05-01
CA2750836A1 (fr) 2010-10-14
JP6210966B2 (ja) 2017-10-11
JP2015096510A (ja) 2015-05-21
US20150299318A1 (en) 2015-10-22
ZA201104545B (en) 2012-03-28
US9751944B2 (en) 2017-09-05
US20140065146A1 (en) 2014-03-06
RU2014147188A (ru) 2016-06-10
IL252561B (en) 2019-02-28
AU2013207589B2 (en) 2016-04-07
CN102272306B (zh) 2017-12-26
MY152033A (en) 2014-08-15
IL213943A0 (en) 2011-07-31
WO2010117011A1 (fr) 2010-10-14
US20110268733A1 (en) 2011-11-03
EP2377932A1 (fr) 2011-10-19
MX343049B (es) 2016-10-21
CO6420359A2 (es) 2012-04-16
JPWO2010117011A1 (ja) 2012-10-18
TW201039852A (en) 2010-11-16
SG172419A1 (en) 2011-07-28
US9079959B2 (en) 2015-07-14
IL213943A (en) 2017-06-29
KR101690340B1 (ko) 2016-12-27
JP5653909B2 (ja) 2015-01-14
CN106317224A (zh) 2017-01-11
BRPI1006134A2 (pt) 2016-02-23
NZ605450A (en) 2014-07-25
EP2377932A4 (fr) 2013-04-24
SG10201401331TA (en) 2014-10-30
KR20120034587A (ko) 2012-04-12
US8575316B2 (en) 2013-11-05
MX2011007342A (es) 2011-07-21

Similar Documents

Publication Publication Date Title
ES2840923T3 (es) Anticuerpo anti-Siglec-15
US9815899B2 (en) Antibody targeting osteoclast-related protein siglec-15
US20150125470A1 (en) Novel anti-siglec-15 antibody
US9464133B2 (en) CDR-modified anti-Siglec-15 antibody
JP7181535B2 (ja) 成長障害を生じない小児骨粗鬆症治療薬